We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00524355
First Posted: September 3, 2007
Last Update Posted: July 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
To describe the frequency, type and severity of the symptoms in patients visiting the GI or internal physicians, with symptoms consistent with gastroesophageal reflux disease (GERD)

Condition
GERD

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of the Gastroesophageal Reflux Disease

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 2717
Study Start Date: March 2007
Study Completion Date: November 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
primary care clinics, private clinics and out-patient department at hospitals in cities and provinces of Viet Nam
Criteria

Inclusion Criteria:

  • Patients from both sexes, aged 18 years or older
  • Patients complaining of symptoms consistent with reflux disease

Exclusion Criteria:

  • Patients with GI cancer and those where the only reason for the visit is renewing the prescription are excluded
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524355


Locations
Vietnam
Research Site
Hanoi, Vietnam
Research Site
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Ta Long, MD, PhD 108 Hospital, Hanoi
Study Chair: Do Van Dung, MD, PhD Ho Chi Minh City Univ of Medicine and Pharmacist
Principal Investigator: Dao Van Long, MD, PhD Ha Noi University of Medicine Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00524355     History of Changes
Other Study ID Numbers: NIS-GVN-NEX-2007/1
NIS-G84-GER-2007/2
First Submitted: August 30, 2007
First Posted: September 3, 2007
Last Update Posted: July 17, 2009
Last Verified: July 2009

Keywords provided by AstraZeneca:
GERD
GIS
heartburn
NIS
PPI